Editorial: Sleeve Gastrectomy Versus Lifestyle Intervention—Redefining the Therapeutic Hierarchy for Adolescent MASLD?

---

The world prevalence of weight problems has risen sharply, with projections suggesting that by 2050, 3.8 billion adults will likely be obese or overweight [1]. Metabolic dysfunction‐related steatotic liver illness (MASLD) is now the most typical explanation for continual liver illness in youngsters and adolescents, rising in parallel with the worldwide improve in paediatric weight problems [2]. MASLD within the younger isn’t a benign situation. Data from massive inhabitants‐primarily based cohort research, together with a Swedish nationwide registry examine [3] and a latest United States retrospective cohort of over 1000 youngsters [4] have demonstrated that childhood‐onset metabolic dysfunction‐related steatohepatitis (MASH) is related to considerably elevated lengthy‐time period mortality danger in early maturity. No pharmacotherapy is at the moment authorised particularly for paediatric MASH. Structured way of life intervention, the present first‐line strategy, achieves histologic MASH decision in lower than one third of kids in managed trials [5].

In adults, bariatric surgical procedure and sleeve gastrectomy specifically, which is now probably the most broadly carried out procedures worldwide, is considerably more practical than way of life modification or optimized medical weight problems remedy in reaching MASH decision and enhancing hepatic fibrosis in addition to lowering lengthy‐time period cardiovascular and hepatic problems [6, 7]. Retrospective cohort research have proven enhancements in liver enzymes and histologic MASH in paediatric sufferers present process bariatric surgical procedure [8]. Yet in adolescents, potential comparative proof with paired liver histology has been virtually totally absent. It is exactly this hole that Yodoshi and colleagues now start to fill [9] (Figure 1).

FIGURE 1.

In a single‐centre potential managed cohort of 42 adolescents aged 12–19 with biopsy‐confirmed MASLD and extreme weight problems (median age 16, median BMI 41 kg/m²), Yodoshi et al. in contrast laparoscopic vertical sleeve gastrectomy (VSG, n = 17) towards a structured multidisciplinary way of life intervention (n = 25) over 52 weeks [9]. Among contributors finishing paired biopsies, enchancment of histological illness exercise occurred in 92% after VSG versus 20% with way of life intervention (danger distinction [RD] 0.68; 95% CI 0.45–0.91). Among these with baseline MASH, decision was achieved in 100% of surgical completers versus 36% (RD 0.16; 95% CI −0.09 to 0.40). Fibrosis improved in 50% versus 7% (RD 0.36; 95% CI 0.12–0.59), and full MASLD decision was noticed in 58% of VSG sufferers and none within the way of life group (RD 0.49; 95% CI 0.26–0.72). Baseline imbalances favoured the approach to life intervention group, making the magnitude of histologic profit after VSG much more notable.

These findings have to be interpreted inside vital methodological boundaries. The cohort is small, nonrandomized, open‐label, and single‐centre. Thirty‐six % of contributors lacked week‐52 biopsies, a dropout fee that dangers choice bias, as completers in each arms usually tend to symbolize therapy responders. In addition, two thirds of the sufferers had no or minimal fibrosis at baseline (phases F0–F1 fibrosis), rendering them as low danger for liver‐associated outcomes. The way of life comparator didn’t embody Glucagon‐like Peptide‐1 (GLP‐1) receptor agonists, now authorised for adolescent weight problems, thereby underestimating the efficacy of therapeutic administration within the non‐surgical group [10].

Yodoshi et al. present rigorous potential histologic proof to point out VSG as a extremely efficient possibility for rigorously chosen adolescents with extreme weight problems and MASLD. Yet they equally expose a discipline’s pressing hole: the absence of head‐to‐head trials evaluating metabolic surgical procedure towards trendy pharmacotherapy in youth with biopsy‐confirmed MASH. MASLD arising in adolescence confers a uniquely lengthy cumulative window for illness development, cardiometabolic morbidity, and untimely mortality. Designing trials with histologic endpoints, adequate energy, and lengthy‐time period observe‐up on this inhabitants is the defining problem for paediatric hepatology within the years forward.

Author Contributions

Ilias Papadimopoulos: writing – evaluation and modifying, conceptualization. Frank Tacke: writing – evaluation and modifying, conceptualization.

Funding

F.T. is supported by the German Research Foundation (DFG CRC/TR 412, Project‐ID 535081457, and SFB1382, Project‐ID 403224013) and below Germany’s Excellence Strategy—EXC 3118/1—venture quantity 533770413.

Conflicts of Interest

F.T.’s lab has acquired analysis grants (funding to the establishment) from AstraZeneca, MSD, Gilead, Agomab. F.T. has acquired honoraria for consulting or lectures from Gilead, Abbvie, Falk, AstraZeneca, Boehringer, Madrigal, MSD, GSK, Ipsen, Mirum, Novo Nordisk, Sanofi.

Papadimopoulos I. and Tacke F., “Editorial: Sleeve Gastrectomy Versus Lifestyle Intervention—Redefining the Therapeutic Hierarchy for Adolescent MASLD?,” Alimentary Pharmacology & Therapeutics
64, no. 6 (2026): 828–830, 10.1111/apt.70810.

Handling Editor: Rohit Loomba

Data Availability Statement

Data sharing not relevant to this text as no datasets had been generated or analysed throughout the present examine.

Linked Articles

This article is linked to Yodoshi et al. papers. To view these articles, go to and https://doi.org/10.1111/apt.70853.

References

• 1.
  GBD 2021 Adult BMI Collaborators
  , “Global, Regional, and National Prevalence of Adult Overweight and Obesity, 1990–2021, With Forecasts to 2050,” Lancet
  405, no. 10481 (2025): 813–838, 10.1016/S0140-6736(25)00355-1.
  [DOI] [PMC free article] [PubMed] [Google Scholar]
• 2.
  Lefere S., Koot B. G. P., Mann J. P., Bufler P., de Bruyne R., and Hudert C. A., “Update in Clinical Science: MASLD in Children and Adolescents,” Journal of Hepatology
  84, no. 6 (2026): 1164–1177, 10.1016/j.jhep.2026.02.016.
  [DOI] [PubMed] [Google Scholar]
• 3.
  Simon T. G., Roelstraete B., Hartjes Okay., et al., “Non‐Alcoholic Fatty Liver Disease in Children and Young Adults Is Associated With Increased Long‐Term Mortality,” Journal of Hepatology
  75 (2021): 1034–1041, 10.1016/j.jhep.2021.06.034.
  [DOI] [PMC free article] [PubMed] [Google Scholar]
• 4.
  Schwimmer J. B., Thai N. Q. N., Noon S. L., et al., “Long‐Term Mortality and Extrahepatic Outcomes in 1096 Children With MASLD: A Retrospective Cohort Study,” Hepatology
  83, no. 3 (2026): 561–574, 10.1097/HEP.0000000000001357.
  [DOI] [PMC free article] [PubMed] [Google Scholar]
• 5.
  Lefere S., Dupont E., De Guchtenaere A., et al., “Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease,” Clinical Gastroenterology and Hepatology
  20 (2022): 2317–2326, 10.1016/j.cgh.2021.11.039.
  [DOI] [PubMed] [Google Scholar]
• 6.
  Aminian A., al‐Kurd A., Wilson R., et al., “Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy‐Proven Nonalcoholic Steatohepatitis,” Journal of the American Medical Association
  326, no. 20 (2021): 2031–2042, 10.1001/jama.2021.19569.
  [DOI] [PMC free article] [PubMed] [Google Scholar]
• 7.
  Verrastro O., Panunzi S., Castagneto‐Gissey L., et al., “Bariatric‐Metabolic Surgery Versus Lifestyle Intervention Plus Best Medical Care in Non‐Alcoholic Steatohepatitis (BRAVES),” Lancet
  401 (2023): 1786–1797, 10.1016/S0140-6736(23)00634-7.
  [DOI] [PubMed] [Google Scholar]
• 8.
  Sundaram S. S., Kelsey M., Nadeau Okay. J., et al., “Resolution of Biochemical and Histologic MASLD in Adolescents With Severe Obesity After Metabolic Bariatric Surgery,” Journal of Pediatrics
  291 (2026): 114944, 10.1016/j.jpeds.2025.114944.
  [DOI] [PubMed] [Google Scholar]
• 9.
  Yodoshi T., Ollberding N. J., McNeill M., et al., “Vertical Sleeve Gastrectomy Versus Comprehensive Lifestyle Intervention for Adolescents With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Controlled Cohort Study,” Alimentary Pharmacology & Therapeutics
  64, no. 6 (2026): 758–769, 10.1111/apt.70766. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 10.
  Weghuber D., Barrett T., Barrientos‐Pérez M., et al., “Once‐Weekly Semaglutide in Adolescents With Obesity,” New England Journal of Medicine
  387 (2022): 2245–2257, 10.1056/NEJMoa2208601.
  [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This part collects any knowledge citations, knowledge availability statements, or supplementary supplies included on this article.

Data Availability Statement

Data sharing not relevant to this text as no datasets had been generated or analysed throughout the present examine.

Linked Articles

This article is linked to Yodoshi et al. papers. To view these articles, go to and https://doi.org/10.1111/apt.70853.

---

Articles from Alimentary Pharmacology & Therapeutics are supplied right here courtesy of Wiley